All In Biotech

Drug Trial Radar · NCT07625293

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

A Phase 2a Study of DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Direct Biologics, LLCIndustry
Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.

Conditions

  • Crohn Disease (CD)

Interventions

  • DB-3QBiological

    bmMSC derived, extracellular vesicle enriched secretome product

  • PlaceboOther

    0.9% Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in SES-CD ScoreTime frame: 12 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University, St. Louis

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.